Researcher

Dr Mark Enea Montebello

Biography

Summary -

Dr Mark Montebello is the Clinical Director and Senior Staff Specialist in Addiction Medicine and Psychiatry, at Drug and Alcohol Services, Northern Sydney Local Health District. He is the Accredited Medical Practitioner for the Royal North Shore Hospital Involuntary Drug and Alcohol Treatment Unit, Member of the Advisory Board of the Australian, New Zealand Journal of Psychiatry, a Honorary Senior Lecturer at the National Drug and...view more

Summary -

Dr Mark Montebello is the Clinical Director and Senior Staff Specialist in Addiction Medicine and Psychiatry, at Drug and Alcohol Services, Northern Sydney Local Health District. He is the Accredited Medical Practitioner for the Royal North Shore Hospital Involuntary Drug and Alcohol Treatment Unit, Member of the Advisory Board of the Australian, New Zealand Journal of Psychiatry, a Honorary Senior Lecturer at the National Drug and Alcohol Research Centre, University of New South Wales, and a Clinical Senior Lecturer, Specialty of Addiction Medicine, Northern Clinical School, University of Sydney.

More information at https://orcid.org/0000-0002-1776-3974

Publications since 2016 -

Grebely J, Read P, Cunningham E, Weltman M, Matthews G, Dunlop A, Montebello M, Martinello M, Gilliver R, Marks P, Applegate T, Dore G. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): an open-label, single-arm, phase 4, multicentre trial. Health Sci Rep (2020) 3:e151. https://doi.org/10.1002/hsr2.151

Mills L, Lintzeris N, Bruno R, Montebello M, Dunlop A, Deacon R, Copeland J, Jefferies M, Rivas C, Mammen K. Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review (2020). DOI: 10.1111/dar.13050 

Jones NR, Shanahan M, Dobbins T, Degenhardt L, Montebello M, Gisev N, Larney S. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia. Drug and Alcohol Review (September 2019), 38, 690–698. DOI: 10.1111/dar.12976

Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Gugusheff J, Phung N, Montebello M, Chan T, Kirby A, Hall M, Jefferies M, Luksza J, Shanahan M, Kevin R, Allsop D. Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. JAMA Intern Med. doi:10.1001/jamainternmed.2019.1993

Jacobs NI, Montebello ME, Monds LA, Lintzeris N. Survey of Australian psychiatrists’ and psychiatry trainees’ knowledge about and attitudes towards medicinal cannabinoids. Australasian Psychiatry (2018) Oct 9: https://doi.org/10.1177/1039856218803675

Lintzeris N, Monds LA, Rivas C, Leung S, Dunlop A, Newcombe D, Walters C, Galea S, White N, Montebello ME, Demirkol A, Swanson N, and Ali R. Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. J Addict Med (2018) 12: 234–240

Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello ME, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N and Agonist Replacement for Cannabis Dependence (ARCD) study group. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry (2018) 18:140

Allsop DJ, Rooney K, Arnold JC, Bhardwaj AK, Raimondo Bruno R, Delwyn J. Bartlett DJ, Montebello ME, Arkell T, Richards E, Gugusheff J, Rooke S, Kerley W, Murnion B, Haber P, McGregor IS, Lintzeris N. Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity 13 (2017) 57-67

Montebello ME, Brett J. Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics. Chapter in book - Non-medical and illicit use of psychoactive drugs. Editors - Suzanne Nielsen, Raimondo Bruno, Susan Schenk. Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 34) p125-139

Broad Research Areas:

Drug Related Harm / Addiction, Psychiatry, Medical Education

Qualifications:
MB BS (UWA), FRANZCP, FAChAM

Specific Research Keywords:
Addiction psychiatry, addiction medicine, cannabis, amphetamines, smoking cessation


My Grants

See research activities above


My Qualifications

MB BS (UWA) FRANZCP FAChAM


My Awards

Winner of the 2019 Australasian Professional Society on Alcohol and other Drugs (APSAD) Clinician of the Year

Winner of the Journal of Addiction Medicine Most Downloaded Article Published in 2018 for “Transferring Patients from Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines.”

Winner of the 1990 University of Western Australia Neuromuscular Disease Research Institute Medical Student Neuropathology Prize


My Research Activities

Projects in progress since 2010 -
Since October 2019: Associate Investigator - DBS HIV Testing Pilot - NSW Dried Blood Spot Self-Sampling HIV and Hepatitis C Testing Pilot Program. Multisite trial led by Dr Anna McNulty, South Eastern Sydney Local Health District. NSW Health funded.

Since September 2019: Principal Investigator - The COQI Cohort Study- Examining clinical outcomes and quality indicators for clients attending NSW public alcohol and other drug (AOD) treatment services. Multisite trial led by Nicholas Lintzeris, South Eastern Sydney Local Health District. NSW Health funded.

Since August 2019: Principal Investigator - Specialist Drug and Alcohol Nurse in General Practice - A Unique Shared Care Model. Collaboration partners - Sydney North Primary Health Network funded ($48,500).

Since December 2018: Principal Investigator - Defining the clinical role of topiramate in the treatment of alcohol dependence in Australia. NH&MRC funded ($718,836). Multisite trial led by Paul Haber, Sydney Local Health District.

Since December 2018: Principal Investigator - CoLAB - An open-label, multicentre, single-arm trial of monthly injections of extended release buprenorphine in people with opioid dependence. Indivior funded ($1,814,536 and study medication). Multisite trial led by Michael Farrell, National Drug and Alcohol Research Centre.

Since September 2018: Associate Investigator - Obtaining normative substance use, health and wellbeing data for clients attending NSW public drug and alcohol (D&A) treatment services. Multisite trial led by Nicholas Lintzeris, South Eastern Sydney Local Health District. NSW Health funded.

Since May 2018: Principal Investigator - ETHOS ENGAGE Study - A non-randomized trial to assess the effect of an intervention incorporating on-site hepatitis C virus RNA testing, liver fibrosis assessment, and linkage to care to enhance scale-up of direct-acting antiviral therapy for hepatitis C virus infection among people with a history of injecting drug use, and either recent injecting drug use or receiving opioid substitution therapy. Multisite trial led by Jason Grebely, Kirby Institute.

Since July 2016: Associate Investigator - REACH-C - Real world Efficacy of Antiviral therapy in Chronic Hepatitis C (Kirby Institute supported but unfunded). Multisite trial led by Greg Dore, Kirby Institute.

Since January 2014: Associate Investigator - Randomised double blind placebo controlled study of lisdexamphetamine for the treatment of methamphetamine dependence. NH&MRC funded ($1,300,000). Collaboration partners - NDARC, St Vincent’s Hospital Sydney, Hunter New England Local Health District, Western Sydney Local Health District, Drug and Alcohol Services South Australia, National Drug Research Institute (NDRI).

Since June 2013: Associate Investigator - A pilot randomised controlled trial of oral varenicline vs oral naltrexone for the treatment of alcohol dependence. NSW Ministry of Health - Mental Health, Drug and Alcohol Office (MHDAO) research grant ($70,000). Collaboration partners - Sydney University, Queensland University of Technology.

Completed projects since 2010 -

2017-2018: Principle Investigator - y-QUIT: smoking cessation and prevention program for young people with severe mental illness. NSW Agency for Clinical Innovation funded ($79,170). Collaboration partners - SESLHD Youth Mental Health Service, UNSW.

2017-2018: Principle Investigator - DARLO-C - Scale-up of treatment for hepatitis C infection among people who inject drugs: A phase IV, open-label, single arm, multicentre trial of elbasvir/grazoprevir for genotype 1 or 4 in people with chronic hepatitis C virus infection and recent injecting drug use. NH&MRC funded/ Pharmaceutical Company sponsored and Kirby Institute supported ($1,300,000). Collaboration partners - St Vincent’s Hospital Sydney, Kirketon Road Centre, local GPs treating patients with HCV.

2016-2018: Principal Investigator - Medicinal Cannabinoids – Education Needs Analysis for Psychiatrists and Psychiatric Trainees. Collaboration partner – RANZCP.

2016-2017: Associate Investigator - Evaluation of the NSW Involuntary Drug and Alcohol Program. NSW Ministry of Health funded ($250,000). Collaboration partners - NDARC and the 2 involuntary drug and alcohol treatment units.

2016-2017: Associate Investigator - Braeburn Buprenorphine (CAM2018) in Adult Outpatients with Opioid Disorder (Pharmaceutical Company sponsored). Collaboration partners - Braeburn company, 10 other international treatment centres.

2014-2015: Associate Investigator - Assertive alcohol and drugs outreach and linkage service to enhance care across hospital and community settings – an integrated model of care for patients with frequent Emergency Department attendance and severe drug and alcohol related problems. SESLHD funded ($350,000). Collaboration partners - Emergency Departments in SESLHD including Prince of Wales Hospital, Sydney & Sydney Eye Hospital, etc.

2014-2017: Associate Investigator - An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients. NH&MRC funded ($762,711.30). Collaboration partners - NDARC, Sydney University, Hunter New England Local Health District, Western Sydney Local Health District.

2013-2017: Associate Investigator - Trialling the clinical guidelines for transfer from methadone to buprenorphine. Indivior sponsored (Total $233,840 and SESLHD allocation $66,771). Collaboration partners - Indivior company, 5 other Australian treatment centres.

2013-2017: Associate Investigator - A randomised controlled trial of exercise for the management of cannabis withdrawal in adult humans. NH&MRC funded ($524,506). Collaboration partners - University of Sydney, Sydney Local Health District, University of Tasmania.

2013-2016: Associate Investigator - Kronic in the Cannabis Clinic. MHDAO research grant ($74,930). Collaboration partners - Sydney University, Hunter New England Local Health District.

2013-2015: Associate Investigator - Developing clinical guidelines for transfer from methadone to buprenorphine. NSW Ministry of Health funded ($180,000). Collaboration partners - 5 other NSW treatment centres.

2013-2014: Associate Investigator - An open-label randomised pragmatic policy trial of nicotine and smokeless tobacco products for quitting or long-term substitution in smokers. NH&MRC funded ($1,100,000). Collaboration partners - Queensland University of Technology.

2013: Principal Investigator - Can exercise and fasting cause re-intoxication in cannabis dependent overweight subjects? University of Sydney funded ($30,000). Collaboration partners - University of Sydney, University of Tasmania.

2011-2013: Chief Investigator - The use of antipsychotic medications amongst OTP patients transferred from Justice Health settings. MHDAO research grant ($14,850). Collaboration partners - NSW Justice and Forensic Mental Health Network.

2010-2013: Principal Investigator - Can exercise and fasting cause re-intoxication in cannabis dependent subjects? University of Sydney funded ($30,000). Collaboration partners - University of Sydney, University of Tasmania.

2010-2013: Associate Investigator - A double blind placebo controlled trial of Sativex® in the management of cannabis withdrawal. NH&MRC funded ($241,283). Collaboration partners - NDARC, Sydney University, Hunter New England Local Health District.

 

View less

Location

Royal North Shore Hospital Community Health Centre
Level 1, 2C Herbert Street
St Leonards, New South Wales, 2065
Australia

Contact

61294629011
61294392973

Publications

by Dr Mark Enea Montebello

ORCID as entered in ROS